Trial Profile
Prospective, single-arm, single center, exploratory clinical study of Apatinib combined with Docetaxel as second line treatment in patients with advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Nov 2017 New trial record